SEC Form 4 · accession 0001209191-17-058480
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stuart A Arbuckle
Officer — EVP\Chief Commercial Officer
Period of report
Oct 27, 2017
Accepted (ET)
Oct 31, 2017 · 6:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 27, 2017 | S | 4,165 | $141.41 | D | 116,952 | D | |
| Common Stock | Oct 27, 2017 | M | 2,125 | $96.87 | A | 119,077 | D | |
| Common Stock | Oct 27, 2017 | S | 2,125 | $149.00 | D | 116,952 | D | |
| Common StockF2,F3 | Oct 31, 2017 | S | 11,617 | $142.18 | D | 105,335 | D | |
| Common StockF3,F4 | Oct 31, 2017 | S | 5,600 | $143.54 | D | 99,735 | D | |
| Common StockF3,F5 | Oct 31, 2017 | S | 25,999 | $144.54 | D | 73,736 | D | |
| Common StockF3,F6 | Oct 31, 2017 | S | 17,501 | $145.34 | D | 56,235 | D | |
| Common StockF3,F7 | Oct 31, 2017 | S | 7,783 | $146.61 | D | 48,452 | D | |
| Common StockF3,F8 | Oct 31, 2017 | S | 5,000 | $147.87 | D | 43,452 | D | |
| Common StockF3,F9 | Oct 31, 2017 | S | 1,000 | $148.54 | D | 42,452 | D | |
| Common Stock | Oct 31, 2017 | S | 500 | $149.34 | D | 41,952 | D | |
| Common Stock | holding | — | — | — | 140 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F10 | $96.87 | Oct 27, 2017 | M | 2,125 | D | — | Jul 14, 2024 | Common Stock | 2,125 | 6,375 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Arbuckle's company-approved trading plan under Rule 10b5-1.
- F10The option vests in 16 quarterly installments from 7/15/2014.
- F2Open market sales reported on this line occurred at a weighted average price of $142.18 (range $141.83 to $142.74).
- F3Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $143.54 (range $143.03 to $144.02).
- F5Open market sales reported on this line occurred at a weighted average price of $144.54 (range $144.04 to $145.01).
- F6Open market sales reported on this line occurred at a weighted average price of $145.34 (range $145.05 to $145.87).
- F7Open market sales reported on this line occurred at a weighted average price of $146.61 (range $146.20 to $147.18).
- F8Open market sales reported on this line occurred at a weighted average price of $147.87 (range $147.22 to $148.20).
- F9Open market sales reported on this line occurred at a weighted average price of $148.54 (range $148.25 to $149.18).